Media releases are provided as is by companies and have not been edited or checked for accuracy. Any queries should be directed to the company itself.
  • 10 December 2019 21:10

Multi Drug Resistant Antibiotics Market :Key Players, SWOT Analysis, Dynamics, Drivers, Key Indicators and Forecast to 2025

The report provides granular level information about The market size, regional market share and forecast from 2019-2025.The report covers in-detail insights about The competitor’s overview, key findings and Their key strategies.The report outlines drivers, restraints, challenges, and trends that are currently faced by The industry.The report tracks recent innovations, key developments and startup’s details that are working in The industry.The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Market Outline: Multi-Drug Resistant Antibiotics Market

Since the discovery of the penicillin in 1928, large amount of antibiotics are used for human therapy, as well as for farm animals and even for fish in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug-resistant may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistant to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, effects a wide range of drugs. Multi drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi drug resistant antibiotics are the new generation antibiotics that fight against the drug resistant bacteria.

Interested in this report?

Access Free Sample Pages of This Report Including TOC, Table, and Figures@  https://www.marketgrowthinsight.com/sample/56410

Market Dynamics: Multi-Drug Resistant Antibiotics Market

Multi drug resistant antibiotics market is driven by the increase in prevalence of the drug resistant bacterial infections such as multi drug resistant TB. In addition, increase in R&D activities to develop the new generation multi drug resistant antibiotics by the marketers coupled with the government and non-government organization's initiatives and fundings are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the multi drug resistant antibiotics market over the forecast period. However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi drug resistance antibiotics market during the forecast period.

Market Scope: Multi Drug Resistant Antibiotics Market

Global multi drug resistant antibiotics market is segmented based on type of bacteria, disease and distribution channel

Based on type of bacteria, it is segmented into
Multi Drug Resistant Enterococci
Multi Drug Resistant Staphylococci
Gram Negatives
Others

Based on disease, it is segmented into
Drug Resistant Tuberculosis
Others

Market Summary: Multi Drug Resistant Antibiotics Market

Emergence of antimicrobial resistance is a major concern, particularly in low and middle-income countries. Multi drug resistance antibiotics market is at growing stage owing to the availability of limited drug resistant antibiotics and there is a huge development need for the novel drugs. The market has many players who are actively participating in the development of the new treatment for multi drug resistant bacterial diseases. For instance, in February 2018, Discuva Ltd., drug discovery company expanded its collaboration with F. Hoffmann-La Roche AG in development of new antibiotic for the life-threatening infections caused by multi drug resistant bacteria and collaboration was originally initiated in February 2014. Furthermore, government and non-government organizations are funding in R&D and spreading awareness related to multi drug resistant antibiotics. Development of novel antibiotics such as plazomicin (in Phase III CL) by Achaogen, Cadazolid (in Phase III CL) by Acetlion Pharmaceuticals and many other companies and their expected commercialization in coming years may drive the market growth furthermore.

Region Anaysis: Multi Drug Resistant Antibiotics Market

Geographically, multi drug resistant antibiotics market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America multi drug resistant market is expected to grow at significant rates owing to the factors such as growing awareness and increase in R&D activities in developing the novel drugs for multi drug resistant infections and well-established healthcare infrastructure. Europe market is driven by the increase in prevalence of the multi drug resistant infections and developed healthcare infrastructure. Asia Pacific multi drug resistant market is expected to grow at notable rates owing to low cost of R&D and expansion of the multinational companies into the developing countries such as India.

Market Participants: Multi Drug Resistant Antibiotics Market

Some of the players in Multi-Drug Resistant Antibiotics Market are F. Hoffmann-La Roche AG (Switzerland), Achaogen Inc. (U.S.), Acetlion Pharmaceuticals (Switzerland), Sanofi S.A (France), Johnson & Johnson Servieces Inc. (U.S.), Pfizer Inc. (U.S.), Otsuka Pharmaceutical (Japan), and Eli Lilly and Company (U.S.) to name a few.

Submit a media release